Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports a good response and tolerability for a combination treatment involving high potency topical corticosteroid, minoxidil 2%, LED, and inosine pranobex in a child with alopecia areata.

In this study, three pediatric patients with alopecia areata and high levels of certain viral antibodies experienced excellent outcomes following treatment with a combination of corticosteroids, minoxidil, inosine pranobex, valacyclovir, and light-emitting diode therapy.

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

This case report describes a 19-year-old female with recurrent alopecia totalis who experienced complete remission after re-treatment with various therapies, emphasizing the importance of long-term follow-up in managing alopecia areata.

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This article discusses the emotional and psychological impact of severe alopecia areata on patients, emphasizing feelings of loss, vulnerability, and self-identity changes, and reports no new results.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

This review discusses various treatment options for alopecia areata, noting a lack of consensus on grading and treatment algorithms, and reports no new clinical results.

This review examines current treatment options for alopecia areata and highlights the challenges due to limited evidence-based data and unpredictability in disease progression.

Minoxidil promotes hair regrowth, but more research needed for effectiveness and response factors.

This study examines the use of diphenylcyclopropenone in treating alopecia areata patients at the University Hospital Würzburg and investigates how the treatment affects patients' quality of life.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This review discusses the efficacy and safety of topical sensitizers for treating alopecia areata and reports no new clinical results; it emphasizes advancements in pediatric use, molecular mechanisms, and targeted delivery methods.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

In this study, L-methionine and L-serine application was observed to have the most significant effect on hair weight and root length, followed by acetyl L-methionine and L-serine, while glutathione inhibited growth.

This article is from the ASPS Education Network and does not report any new research findings.

This study investigated adenosine-to-inosine RNA editing in the hair follicle cycle of Tianzhu white yak, identifying numerous editing sites and suggesting their involvement in pathways related to hair growth.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

This review discusses the current understanding of propranolol's use in treating infantile hemangiomas, covering its indications, effectiveness, side effects, and ongoing clinical trials, without presenting new clinical results.

Propranolol can cause reversible hair loss.